Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 4,175 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control comparison Clear all

Conditions: Cellulite
Interventions: cryolipolysis, Subcision, Control; Device · Procedure · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV Infections
Interventions: Lamivudine/Zidovudine, HIV-1 Immunogen, Nelfinavir mesylate; Drug · Biological
Lead sponsor: Agouron Pharmaceuticals; Industry
Eligibility: 13 Years and older
Enrollment: 688 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: San Diego, California

Conditions: Dental Caries
Interventions: 0.24% Sodium Fluoride Dentifrice, 1.5% Arginine Dentifrice, 4.0% Arginine Dentifrice, 8.0% Arginine Dentifrice; Drug
Lead sponsor: Colgate Palmolive; Industry
Eligibility: 10 Years to 14 Years
Enrollment: 2,025 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 8
States / cities: Loma Linda, California • Gainesville, Florida • Indianapolis, Indiana + 4 more

Conditions: Alzheimer Disease
Interventions: Placebo, BI 409306, Donepezil; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 55 Years and older
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 10
States / cities: Sherman Oaks, California • Orlando, Florida • West Palm Beach, Florida + 7 more

Conditions: Healthy Non-dependent, Recreational Sedative Users, Abuse Potential
Interventions: Suvorexant, Zolpidem, Seltorexant, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 127 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Prevention of Meningococcal Disease
Interventions: MenACWY-CRM Vaccine, MenACWY-PS Vaccine; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 12 Months to 10 Years
Enrollment: 910 participants
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Oakland, California

Conditions: Acne Vulgaris
Interventions: UHE-101 Cream, Vehicle Cream; Drug · Other
Lead sponsor: Therapeutics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Diego, California

Conditions: Asthma
Interventions: Experimental: Standard vs Intensive e-AT Intervention; Other
Lead sponsor: University of Utah; Other
Eligibility: 2 Years to 17 Years
Enrollment: 926 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Blood Loss During Vaginal Hysterectomy
Interventions: Vasopressin; Drug
Lead sponsor: Ascher-Walsh, Charles, M.D.; Individual
Eligibility: 18 Years and older · Female only
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: New York, New York

Conditions: Vision, Low, Blindness
Interventions: Interaction with Mock COVID-19 Rapid Antigen Test and Reference Surfaces, Biomechanical Measurements, Psychophysical Tasks; Diagnostic Test · Behavioral
Lead sponsor: University of Delaware; Other
Eligibility: 12 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Healthy
Interventions: Oxycodone controlled-release test formulation, Immediate-release reference drug; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Glioblastoma, Glioblastoma, WHO Grade IV
Interventions: Temozolomide (TMZ), Optune System, Pembrolizumab; Drug · Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Diabetes
Interventions: Saxagliptin, Dapagliflozin, Glimepiride, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 22
States / cities: Birmingham, Alabama • Chandler, Arizona • Tempe, Arizona + 17 more

Conditions: Kidney Transplantation
Interventions: Kidney Biopsy, Rapamune (sirolimus/rapamycin), Tacrolimus; Procedure · Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Solid Tumor, Solid Tumor, Adult, Solid Tumor, Unspecified, Adult
Interventions: CONVO intervention; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 5
States / cities: New York, New York • The Bronx, New York

Conditions: Multiple Sclerosis, Pathologic Processes, Demyelinating Autoimmune Diseases, CNS, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Demyelinating Diseases, Autoimmune Diseases, Immune System Diseases
Interventions: Music Training Intervention, Music Listening; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 80 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hidradenitis Suppurativa
Interventions: Sonelokimab, Placebo; Drug
Lead sponsor: MoonLake Immunotherapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 30
States / cities: Birmingham, Alabama • North Little Rock, Arkansas • Fountain Valley, California + 27 more

Conditions: Spinal Stenosis
Interventions: Interspinous Spacer device, Interspinous Process Distraction Device; Device
Lead sponsor: Synthes USA HQ, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 10
States / cities: Santa Monica, California • New Haven, Connecticut • Minneapolis, Minnesota + 7 more

Conditions: Degenerative Disc Disease, Pain
Interventions: Injectable placental tissue extract called BioDGenesis (Active Product), Placebo; Drug
Lead sponsor: Semmes-Murphey Foundation; Other
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Puyallup, Washington, Washington

Conditions: Behavioral Inhibition, Anxiety
Interventions: Parent Psychoeducation, Turtle Program; Behavioral
Lead sponsor: University of Maryland, College Park; Other
Eligibility: 42 Months to 60 Months
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: College Park, Maryland

Conditions: Pain, Postoperative, Arthroplasty Complications
Interventions: Ketamine; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Renal Failure
Interventions: MediHoney; Biological
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years to 90 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Heart Failure
Interventions: CardioMEMS; Device
Lead sponsor: STAVROS G DRAKOS; Other
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Lexington, Kentucky • Falls Church, Virginia

Conditions: Chronic Kidney Disease and Hypertension
Interventions: Baxdrostat/dapagliflozin, Placebo/dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 133
States / cities: Fairhope, Alabama • Sun City, Arizona • Tucson, Arizona + 117 more

Search by objective public record fields.

Cryolipolysis and Subcision for Treatment of Cellulite

Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)

A Clinical Trial to Assess the Safety and the Anti-caries Efficacy of COL 101 (Arginine) Non-fluoride Dentifrices in Comparison With 0.24% Sodium Fluoride (1100 Ppm F) Dentifrice Control in 10 to 14-year-old Children

BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.

A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem

Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Children

A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris

Redesigning Ambulatory Care Delivery to Enhance Asthma Control in Children

Comparison of the Effects of Cervical Vasopressin Versus no Premedication on Blood Loss During Vaginal Hysterectomy: A Randomized, Placebo Controlled Trial

Validation of Texture Changing Coatings for Use in At-Home Rapid Tests

A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers

Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)

A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal

Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values

Ukulele Playing to Improve Cognition in People with Multiple Sclerosis: a Feasibility Study

Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

A Study of the In-Space Device for Treatment of Moderate Spinal Stenosis

Efficacy of Intradiscal Injection of Viable Placental Tissue Extract in Subjects With One or Two Level, Symptomatic Lumbar Intervertebral Disc Degeneration

A Multi-Method Early Intervention Program for Inhibited and Anxious Preschoolers

Intraoperative Ketamine for Patients Undergoing Total Joint Arthroplasty

The Efficacy of "MediHoney" to Facilitate Catheter Exit-Site Surgical Wound Healing

TARGET-LOAD Pilot Study Comparing Hemodynamics-guided LVAD Unloading Vs. Standard of Care

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure